Recent studies have shown that LITAF is frequently down-regulated in different types of cancer [20], including acute leukemia [17], breast cancer [16, 21], lymphoma [22, 23], and prostatic cancer [24], suggesting that it may function as a tumor suppressor gene. Here, LITAF is linked to prostate carcinoma.